Tell Us What You Think

Rate your Quintiles.com experience

Subscribe to Email Based on Your Interests

Set preferences

Information Library

Case Studies - Diabetes/Endocrinology

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by: Most Recent
  • Title
  • Takeda Hits the Ground Running in New European Territory, with Help from Innovex

    September 25, 2009
    Our customer was faced with the challenge to launch a countrywide sales team in Spain within 12 weeks.

  • Controlling Diabetes in Spain

    September 23, 2009
    Spain has a real problem with diabetes: up to 10% of the population has the disease and it’s a killer, representing the 3rd highest cause of death amongst women.

  • Maximizing Post-Marketing Research for Robust ROI

    September 18, 2009
    Quintiles leveraged its expertise and resources in a large-scale observational study to produce valuable post-marketing data for commercial success.

  • Simplifying a Complex Study with Precision Planning

    September 17, 2009
    Quintiles leveraged its data management expertise and strategic planning to deliver high-quality data from a complex large-scale, multi-country study.

  • Diabetes Case Study

    September 9, 2009
    Case Study about patient identification and successful intervention to positively health outcomes for patients in UK.

  • Diabetes Outcomes

    September 8, 2009
    This Phase IIIB diabetes study involved cardiovascular outcomes assessed over 6 years. Learn how Quintiles helped the customer overcome the challenges of patient retention, data collection and evaluation.

  • Diabetes

    March 27, 2009
    A dose-ranging clinical study to evaluate the safety, efficacy and tolerability of five doses of Drug X compared with placebo in Type II diabetes patients with no prior exposure to anti-diabetic medication